Carrick Therapeutics Limited

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…

This study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a common type of advanced breast cancer (HR+/HER2-). The goal was to find a safe dose and see if it can slow the cancer's growth. Participants had already tried other treatments and thei…

This study tested whether adding the experimental drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with advanced HR+/HER2- breast cancer. The trial enrolled 60 adults whose cancer had worsened despite prior treatment. Rese…